Point72 Asset Management L.P. Invests $352,000 in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Point72 Asset Management L.P. purchased a new position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 26,600 shares of the company's stock, valued at approximately $352,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. First Trust Advisors LP grew its holdings in shares of Takeda Pharmaceutical by 2.0% in the 4th quarter. First Trust Advisors LP now owns 3,240,932 shares of the company's stock worth $42,910,000 after acquiring an additional 62,718 shares during the period. Van ECK Associates Corp grew its holdings in shares of Takeda Pharmaceutical by 1.6% in the 4th quarter. Van ECK Associates Corp now owns 2,210,428 shares of the company's stock worth $29,266,000 after acquiring an additional 35,192 shares during the period. Northern Trust Corp grew its holdings in shares of Takeda Pharmaceutical by 14.6% in the 4th quarter. Northern Trust Corp now owns 1,873,588 shares of the company's stock worth $24,806,000 after acquiring an additional 238,161 shares during the period. Summit Global Investments grew its holdings in shares of Takeda Pharmaceutical by 75.5% in the 4th quarter. Summit Global Investments now owns 729,200 shares of the company's stock worth $9,655,000 after acquiring an additional 313,642 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in shares of Takeda Pharmaceutical by 15,449.0% in the 4th quarter. BNP Paribas Financial Markets now owns 500,677 shares of the company's stock worth $6,629,000 after acquiring an additional 497,457 shares during the period. Institutional investors and hedge funds own 9.17% of the company's stock.

Takeda Pharmaceutical Price Performance

NYSE:TAK traded up $0.16 during trading hours on Thursday, reaching $14.75. 442,325 shares of the company traded hands, compared to its average volume of 1,924,848. The firm's 50-day moving average is $14.66 and its 200-day moving average is $14.03. The stock has a market cap of $46.92 billion, a P/E ratio of 36.89, a P/E/G ratio of 0.24 and a beta of 0.26. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. Takeda Pharmaceutical Company Limited has a 1-year low of $12.58 and a 1-year high of $15.43.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). The company had revenue of $7.34 billion for the quarter, compared to analyst estimates of $8.02 billion. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Equities research analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.